These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 25363310)

  • 1. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
    Fogel LE; Ray CJ
    Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 3. Supreme Court rules against Teva in Copaxone® patent fight.
    Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):350-1. PubMed ID: 26900611
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
    [No Abstract]   [Full Text] [Related]  

  • 5. Canada to change patent law to allow export of cheap drugs.
    Kondro W
    Lancet; 2003 Oct; 362(9392):1290. PubMed ID: 14577437
    [No Abstract]   [Full Text] [Related]  

  • 6. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
    Sklan A
    Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 8. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canada ordered to implement WTO ruling against "stockpiling" of generic drugs.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2000; 5(4):27. PubMed ID: 11833161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is India ready to lead the battle for fair access to medicines?
    Lancet Oncology
    Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
    [No Abstract]   [Full Text] [Related]  

  • 11. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 12. Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.
    Roehr B
    BMJ; 2012 Dec; 345():e8464. PubMed ID: 23236054
    [No Abstract]   [Full Text] [Related]  

  • 13. Preliminary injunctions in generic and branded patent litigation.
    Cohen S; England P
    Expert Opin Ther Pat; 2013 Sep; 23(9):1083-6. PubMed ID: 23855903
    [No Abstract]   [Full Text] [Related]  

  • 14. Running short.
    Mettner J
    Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 16. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
    Garrigues A
    J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443
    [No Abstract]   [Full Text] [Related]  

  • 17. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: cost savings.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
    [No Abstract]   [Full Text] [Related]  

  • 19. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles?
    Hollis A
    Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123
    [No Abstract]   [Full Text] [Related]  

  • 20. The Impact of Off-Patent Drug Acquisitions on Prices.
    Gupta R; Henkel A; Forman HP; Ross JS
    J Gen Intern Med; 2018 Jul; 33(7):1007-1009. PubMed ID: 29687433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.